Inhibition of intestinal absorption of cholesterol by surface-modified nanostructured aluminosilicate compounds

Journal of Pharmaceutical Sciences

Volumn 98, Issue 7, 2009, Pages 2390-2400

  Gershkovich, Pavel ^a   Darlington, Jerry ^b   Sivak, Olena ^a   Constantinides, Panayiotis P ^c   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Technical Center   (United States)

^c Biopharmaceutical and Drug Delivery Consulting   (United States)

Author keywords

Adsorption; Biomaterials; Colloid; Gastrointestinal; Inhibition; Intestinal absorption; Lipids; Micelle; Natural products; Oral absorption

Indexed keywords

ALUMINUM SILICATE; CHOLESTEROL; EZETIMIBE; INTRALIPID; NANOMATERIAL; SITOSTANOL;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG FORMULATION; INTESTINE ABSORPTION; ION EXCHANGE; MALE; NONHUMAN; PROTON TRANSPORT; RADIOACTIVITY; RAT; SURFACE PROPERTY; SUSPENSION;

EID: 67650324000     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21616     Document Type: Article

References (42)

1. Wang DQ. 2007. Regulation of intestinal cholesterol absorption. Annu Rev Physiol 69:221-248.
2. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr., Stone NJ. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 24:149-161.
3. Kruit JK, Groen AK, van Berkel TJ, Kuipers F. 2006. Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 12: 6429-6439. (Pubitemid 44742578)
4. Harper CR, Jacobson TA. 2007. The broad spectrum of statin myopathy: From myalgia to rhabdomyolysis. Curr Opin Lipidol 18:401-408. (Pubitemid 47051918)
5. Davidson MH, Robinson JG. 2007. Safety of aggressive lipid management. J Am Coll Cardiol 49:1753-1762.
6. Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM. 2006. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation 114:2788-2797. (Pubitemid 46018281)
7. Kesaniemi YA, Miettinen TA. 1987. Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 17:391-395. (Pubitemid 18063904)
8. Santosa S, Varady KA, AbuMweis S, Jones PJ. 2007. Physiological and therapeutic factors affecting cholesterol metabolism: Does a reciprocal relationship between cholesterol absorption and synthesis really exist? Life Sci 80:505-514.
9. Huff MW, Pollex RL, Hegele RA. 2006. NPC1 L1: Evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol 26:2433-2438. (Pubitemid 44607462)
10. Patel SB. 2004. Ezetimibe: A novel cholesterol-lowering agent that highlights novel physiologic pathways. Curr Cardiol Rep 6:439-442. (Pubitemid 39585761)
11. Bitzur R, Cohen H, Harats D. 2006. Cholesterol absorption as a target for the treatment of hypercholesterolemia. Harefuah 145:831-835, 860, 861.
12. Wierzbicki AS. 2004. Lipid-altering agents: The future. Int J Clin Pract 58:1063-1072.
13. Florentin M, Liberopoulos EN, Elisaf MS. 2008. Ezetimibe-associated adverse effects: What the clinician needs to know. Int J Clin Pract 62:88-96. (Pubitemid 350294010)
14. Maki KC, Davidson MH, Umporowicz DM, Schaefer EJ, Dicklin MR, Ingram KA, Chen S, McNamara JR, Gebhart BW, Ribaya-Mercado JD, Perrone G, Robins SJ, Franke WC. 2001. Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet. Am J Clin Nutr 74:33-43. (Pubitemid 32574909)
15. Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. 1995. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 333: 1308-1312.
16. Ostlund RE, Jr., Racette SB, Okeke A, Stenson WF. 2002. Phytosterols that are naturally present in commercial corn oil significantly reduce cholesterol absorption in humans.AmJ ClinNutr 75:1000-1004.
17. Sudhop T, von BergmannK. 2004. Sitosterolemia - A rare disease. Are elevated plant sterols an additional risk factor? Z Kardiol 93:921-928.
18. Patel MD, Thompson PD. 2006. Phytosterols and vascular disease. Atherosclerosis 186:12-19.
19. Assmann G, Cullen P, Erbey J, Ramey DR, Kannenberg F, Schulte H. 2006. Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: Results of a nested casecontrol analysis of the Prospective Cardiovascular Munster (PROCAM) study. Nutr Metab Cardiovasc Dis 16:13-21.
20. Cai Y, Meng XF, Cao YX, Lu H, Zhu SF, Zhou LZ. 2006. Montmorillonite ameliorates hyperthyroidism of rats and mice attributed to its adsorptive effect. Eur J Pharmacol 551:156-161. (Pubitemid 44648049)
21. 2+-loaded montmorillonite. Br Poult Sci 49:65-73.
22. Carretero MI. 2002. Clay minerals and their bene- ficial effects upon human health. Appl Clay Sci 21: 155-163. (Pubitemid 34731603)
23. Afriyie-Gyawu E, Mackie J, Dash B, Wiles M, Taylor J, Huebner H, Tang L, Guan H, Wang JS, Phillips T. 2005. Chronic toxicological evaluation of dietary NovaSil clay in Sprague-Dawley rats. Food Addit Contam 22:259-269. (Pubitemid 40778725)
24. Wang JS, Luo H, Billam M, Wang Z, Guan H, Tang L, Goldston T, Afriyie-Gyawu E, Lovett C, Griswold J, Brattin B, Taylor RJ, Huebner HJ, Phillips TD. 2005. Short-term safety evaluation of processed calcium montmorillonite clay (NovaSil) in humans. Food Addit Contam 22:270-279. (Pubitemid 40778726)
25. Phillips TD, Lemke SL, Grant PG. 2002. Characterization of clay-based enterosorbents for the prevention of aflatoxicosis. Adv Exp Med Biol 504: 157-171. (Pubitemid 34457487)
26. Madkour AA, Madina EM, el-Azzouni OE, Amer MA, el-Walili TM, Abbass T. 1993. Smectite in acute diarrhea in children: A double-blind placebocontrolled clinical trial. J Pediatr Gastroenterol Nutr 17:176-181.
27. Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L. 2005. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: A randomized, controlled trial. Aliment Pharmacol Ther 21:435-444. (Pubitemid 40313947)
28. Bhattacharyya KG, Gupta SS. 2008. Adsorption of a few heavy metals on natural and modified kaolinite and montmorillonite: A review. Adv Colloid Interface Sci 140:114-131.
29. Sternberg TH, Taylor DR. 1951. Fused bentonite sulphur as a topical medication. Urol Cutan Rev 55:348-352.
30. Saary J, Qureshi R, Palda V, DeKoven J, Pratt M, Skotnicki-Grant S, Holness L. 2005. A systematic review of contact dermatitis treatment and prevention. J Am Acad Dermatol 53:845. (Pubitemid 41501373)
31. Elmore AR. 2003. Final report on the safety assessment of aluminum silicate, calcium silicate, magnesium aluminum silicate, magnesium silicate, magnesium trisilicate, sodium magnesium silicate, zirconium silicate, attapulgite, bentonite, Fuller's earth, hectorite, kaolin, lithium magnesium silicate, lithium magnesium sodium silicate, montmorillonite, pyrophyllite, and zeolite. Int J Toxicol 22: 37-102. (Pubitemid 36926229)
32. Viseras C, Lopez-Galindo A. 2000. Characteristics of pharmaceutical grade phyllosilicate powders. Pharm Dev Technol 5:47-52. (Pubitemid 30069198)
33. Puranik PK, Manekar NC, Dorle AK. 1992. Preparation and evaluation of abietic acid microcapsules by a solvent evaporation technique. J Microencapsul 9:425-435.
34. Kristensen J, Schaefer T, Kleinebudde P. 2002. Development of fast-disintegrating pellets in a rotary processor. Drug Dev Ind Pharm 28:1201-1212. (Pubitemid 35416649)
35. Meshali MM. 1982. Adsorption of phenazopyridine hydrochloride on pharmaceutical adjuvants. Pharmazie 37:718-720.
36. Nikkila E, Oker-Blom N. 1952. Effect of treatment of bentonite on serum protein, lipid phosphorus, and cholesterol. Ann Med Exp Biol Fenn 30:51-58.
37. Peluso MR, Schneeman BO. 1994. A food-grade silicon dioxide is hypocholesterolemic in the diet of cholesterol-fed rats. J Nutr 124:853-860. (Pubitemid 24200590)
38. Clarey M, Edwards J, Tsipursky SJ, Beall GW, Eisenhour DD. 2000. Method of manufacturing polymer-grade clay for use in nanocomposites. US Patent 6050509.
39. Wasan KM, Holtorf L, Subramanian R, Cassidy SM, Pritchard PH, Stewart DJ, Novak E, Moghadasian MH. 2001. Assessing plasma pharmacokinetics of cholesterol following oral coadministration with a novel vegetable stanol mixture to fasting rats. J Pharm Sci 90:23-28. (Pubitemid 32050473)
40. Carr TP, Gallaher DD, Yang CH, Hassel CA. 1996. Increased intestinal contents viscosity reduces cholesterol absorption efficiency in hamsters fed hydroxypropyl methylcellulose. J Nutr 126:1463-1469. (Pubitemid 26137705)
41. Sivak O, Gershkovich P, Darlington J, Constantinides P, Wasan KM. 2008. American Association of Pharmaceutical Scientists Annual Meeting and Exposition, Atlanta, GA, USA, November.
42. Madejova J, Bujdak J, Janek M, Komadel P. 1998. Comparative FT-IR study of structural modifications during acid treatment of dioctahedral smectites and hectorite. Spectrochimica Acta A 54:1397-1406. (Pubitemid 128412560)